Please assess the completion status of the following clinical trial:

Trial Title: Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent before initiation of any study related procedures~2. Male or non-pregnant female aged 18 to ≤ 75 years~3. Referred for PCI or structural cardiac intervention and planned to receive bivalirudin treatment~4. Only subjects in whom the treating physician feels that clopidogrel and prasugrel are equivalent on the basis of available clinical literature will be included.~Exclusion Criteria:~1. Currently receiving glycoprotein IIb/IIIa inhibitors.~2. Have received prasugrel or clopidogrel within 2 weeks~3. Serum creatinine level \>2.0~4. Hypersensitivity to bivalirudin, prasugrel, clopidogrel or aspirin~5. Currently on heparin administration or administered ≤ 4.5 h prior to intervention~6. Thrombocytopenia (\<50,000/µL)~7. Severe systemic hypertension defined as systolic blood pressure \>180 mm Hg and/or diastolic blood pressure \>110 mm Hg~8. Body weight \< 60 kg~9. Cardiogenic shock~10. Acute pericarditis~11. Active internal bleeding~12. History of bleeding diathesis within previous thirty days~13. Any history of intracranial hemorrhage, Transient ischemic attack (TIA ) or stroke~14. Arteriovenous malformations or aneurysms~15. Major surgical procedures or severe physical trauma within last thirty days.~16. Symptoms or findings suggestive of aortic dissection~17. Pregnancy~18. Participation in other clinical research studies involving the evaluation of investigational drugs or devices within 30 days of enrollment~19. Incompetent subjects or subjects otherwise unable to provide informed consent~20. Subjects in whom the treating physician believes that one agent (prasugrel or clopidogrel) is preferable over the other will be excluded from study participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Prasugrel (Type: ACTIVE_COMPARATOR): Prasugrel oral loading dose of 60 mg administered preceding cardiac intervention
- Clopidogrel (Type: ACTIVE_COMPARATOR): Clopidogrel oral loading dose of 600 mg administered preceding cardiac intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).